Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs

Carolina Terragna, Marina Martello, Barbara Santacroce, Vincenza Solli, Lucia Pantani, Elena Zamagni, Paola Tacchetti, Beatrice Anna Zannetti, Katia Mancuso, Giulia Marzocchi, Nicoletta Testoni, Gaia Ameli, Rosalinda Termini, Flores A Dico, Enrica Borsi, Giovanni Martinelli, Michele Cavo

Blood (2016) 128 (22): 2080.

https://doi.org/10.1182/blood.V128.22.2080.2080

Published: 2016

Journal Articles

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

Blood (2014) 124 (21): 3400.

https://doi.org/10.1182/blood.V124.21.3400.3400

Published: 2014

Journal Articles

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Gay, MD, Annalisa Pezzi, Statistician, Marilena Bellò, MD, Ilaria Rambaldi, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Valeria Magarotto, MD, Beatrice Anna Zannetti, MD, Massimo Menga, MD, Giulia Marzocchi, PhD, Carolina Terragna, PhD, Katia Mancuso, MD, Antonio Palumbo, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2014) 124 (21): 3371.

https://doi.org/10.1182/blood.V124.21.3371.3371

Published: 2014

Journal Articles

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Annamaria Brioli, MD, Annalisa Pezzi, Statistician, Daniele Derudas, MD, Maria Concetta Petti, MD, Beatrice Anna Zannetti, MD, Felicetto Ferrara, MD, Serena Rocchi, MD, Francesco Nobile, MD, Anna Baraldi, MD, Pellegrino Musto, MD, Francesco Lanza, MD, Katia Mancuso, MD, Letizia Canepa, MD, Lucio Catalano, MD, Antonio Lazzaro, MD, Graziella Pinotti, MD, Mario Boccadoro, MD, Michele Cavo, MD

Blood (2014) 124 (21): 1182.

https://doi.org/10.1182/blood.V124.21.1182.1182

Published: 2014

Journal Articles

Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib

Paola Tacchetti, MD, Serena Rocchi, MD, Annalisa Pezzi, Elena Zamagni, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Katia Mancuso, MD, Annamaria Brioli, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1859.

https://doi.org/10.1182/blood.V122.21.1859.1859

Published: 2013

Journal Articles

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Elena Zamagni, MD, Cristina Nanni, MD, Annalisa Pezzi, Statistics, Katia Mancuso, Paola Tacchetti, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Annamaria Brioli, MD, Serena Rocchi, MD, Giulia Marzocchi, PhD, Nicoletta Testoni, BS, Carolina Terragna, PhD, Giovanni Martinelli, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1936.

https://doi.org/10.1182/blood.V122.21.1936.1936

Published: 2013

Journal Articles

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Carolina Terragna, PhD, Marina Martello, Enrica Borsi, PhD, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Brioli Annamaria, MD, Beatrice Anna Zannetti, MD, Flores Dico, Nicoletta Testoni, BS, Giulia Marzocchi, PhD, Katia Mancuso, MD, Serena Rocchi, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1855.

https://doi.org/10.1182/blood.V122.21.1855.1855

Published: 2013

Journal Articles

Superior Outcomes With Bortezomib Or Thalidomide Incorporated Into Autologous Stem Cell Transplantation (ASCT) Versus Novel Agent-Based Treatments For Elderly Patients With Newly Diagnosed Multiple Myeloma (MM): A Case-Match Comparison

Blood (2013) 122 (21): 3344.

https://doi.org/10.1182/blood.V122.21.3344.3344

Published: 2013

Journal Articles

SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma

Enrica Borsi, Giulia Perrone, MD, Carolina Terragna, PhD, Marina Martello, Manuela Mancini, PhD, Elisa Leo, PhD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2012) 120 (21): 574.

https://doi.org/10.1182/blood.V120.21.574.574

Published: 2012

Journal Articles

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Blood (2011) 118 (21): 1821.

https://doi.org/10.1182/blood.V118.21.1821.1821

Published: 2011

Journal Articles

HIF 1 Alpha: A Suitable Target for Multiple Myeloma

Giulia Perrone, MD, Enrica Borsi, PhD, Carolina Terragna, PhD, Sandra Durante, Marina Martello, Michela Aluigi, PhD, Manuela Mancini, PhD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Giovanni Martinelli, MD, Maria Alessandra Santucci, MD, Michele Baccarani, MD, Michele Cavo, MD

Blood (2011) 118 (21): 2901.

https://doi.org/10.1182/blood.V118.21.2901.2901

Published: 2011

Journal Articles

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

Carolina Terragna, PhD, Marina Martello, Sandra Durante, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Giulia Perrone, MD, Beatrice Anna Zannetti, MD, Enrica Borsi, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2011) 118 (21): 3935.

https://doi.org/10.1182/blood.V118.21.3935.3935

Published: 2011

Journal Articles

Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Patriarca, MD, Annalisa Pezzi, Statistician, Beatrice Anna Zannetti, MD, Paola Tacchetti, MD, Emanuela Englaro, MD, Giulia Perrone, MD, Silvia Buttignol, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Francesca Carobolante, MD, Michele Baccarani, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2011) 118 (21): 826.

https://doi.org/10.1182/blood.V118.21.826.826

Published: 2011

Journal Articles

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Blood (2010) 116 (21): 3562.

https://doi.org/10.1182/blood.V116.21.3562.3562

Published: 2010

Journal Articles

Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study

Elena Zamagni, Cristina Nanni, Francesca Patriarca, Paola Tacchetti, Emanuela Englaro, Giulia Perrone, Silvia Buttignol, Annamaria Brioli, Lucia Pantani, Beatrice Anna Zannetti, Francesca Caroborante, Michele Baccarani, Stefano Fanti, Michele Cavo

Blood (2010) 116 (21): 369.

https://doi.org/10.1182/blood.V116.21.369.369

Published: 2010

NARROW

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Superior Outcomes With Bortezomib Or Thalidomide Incorporated Into Autologous Stem Cell Transplantation (ASCT) Versus Novel Agent-Based Treatments For Elderly Patients With Newly Diagnosed Multiple Myeloma (MM): A Case-Match Comparison

SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

HIF 1 Alpha: A Suitable Target for Multiple Myeloma

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only